Gilead $1,100 a day drug. Now it will launch a generic at quarter the price

Gilead charged $1,100 a day for this drug. Now it will launch a generic at quarter the price
By Ron Leuty – Reporter, San Francisco Business Times
A generic version of Harvoni — one in a series of life-changing hepatitis C drugs Gilead Sciences Inc. introduced four years ago at a price of over $1,000 a pill — will hit the market early next year at a quarter the price of the branded drug.

But while lower-priced generics generally a problem for drug makers because they eat into revenue, Foster City-based Gilead (NASDAQ: GILD) is looking forward to the generic: It will keep control of the drug and expand its market.

The "authorized generics" of Harvoni and another Gilead hepatitis C drug, Epclusa, will be marketed under the flag of Asegua Therapeutics LLC, a new Gilead subsidiary.

Read more:

 https://www.bizjournals.com/sanfrancisco/news/2018/10/29/gilead-gild-generic-hepatitis-c-harvoni-epclusa.html

On This Blog
The controversy over expensive new drugs for hepatitis C
Link to a collection of current research articles regarding the effectiveness and safety of generic hepatitis C medicines. Read news articles addressing the high cost, insurance restrictions; private insurers/Medicaid and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"